The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000543381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
15/04/2026
Date registered
Help: Date registered
30/04/2026
Date last updated
Help: Date last updated
28/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
30/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Polygenic Risk-Enhanced Detection and Initiation of Glaucoma Treatment: Feasibility Study
Scientific title
Feasibility Assessment for Streamlined Testing in the Polygenic Risk-Enhanced Detection and Initiation of glauComa Treatment trial (FAST-PREDICT) for adult glaucoma suspect referrals
Additional trial identifiers [1] 317035 0
Nil
Universal Trial Number (UTN)
Trial acronym
FAST-PREDICT
Related trial records

Health condition
Health condition(s) studied:
Glaucoma 341530 0
Glaucoma suspects 341531 0
Condition category
Condition code
Eye 337606 337606 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
RAPID GLAUCOMA EVALUATION CLINIC
Eligible participants will be invited to a Rapid Glaucoma Evaluation Clinic (RGEC) where they will:

1. Undergo diagnostic examinations (Visual Acuity, Automated Refraction, automated perimetry, intraocular pressure (IOP) and corneal thickness measurement, optical coherence tomography of the anterior segment, macula and optic nerve head, and colour fundus photography)
2. Provide a saliva swab for a NATA-accredited glaucoma polygenic risk score (SightScore)

RISK STRATIFICATION PHASE
The collected diagnostic information will be inputted into a combined clinical-polygenic risk calculator which will provide a 5 year percentage risk estimate of treatment initiation. The participants will be informed of their risk stratification within 4 to 6 weeks of clinic attendance and instructed on the designated follow-up pathway:

- High Risk: allocated to a glaucoma subspecialty clinic waitlist
- Intermediate/Medium Risk: reviewed every 6 months in a dedicated glaucoma monitoring clinic
- Low Risk: reviewed every 12 months in a dedicated glaucoma monitoring clinic

FOLLOW UP PHASE
Once the stratification and allocation to care pathway has been completed, clinical care of participants is at the discretion of the clinician. However, all participants will remain enrolled for 24 months from time of enrolment, and their notes from each subsequent clinical visit reviewed for evidence of conversion to glaucoma, defined as the development of a reproducible glaucomatous visual field defect, reproducible IOP > 28 mmHg or reduction in circumpapillary retinal nerve fibre layer (RNFL) thickness of >10% from baseline in either superior or inferior quadrant.
Intervention code [1] 333791 0
Early detection / Screening
Description of the comparator or control
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345105 0
Fidelity of the RGEC (assessed as a composite outcome)
Timepoint [1] 345105 0
Conclusion of study
Primary outcome [2] 345106 0
Acceptability of the RGEC to patients and clinic stakeholders
Timepoint [2] 345106 0
Patients: at the conclusion of RGEC visit Clinic Stakeholders: 4 weeks from conclusion of feasibility study
Primary outcome [3] 345107 0
Safety of RGEC (measured as composite outcome)
Timepoint [3] 345107 0
Conclusion of RGEC visit and at 3 months post conclusion of feasibility study
Secondary outcome [1] 460471 0
Does the RGEC support effective triage (assessed as composite outcome)
Timepoint [1] 460471 0
1 year from conclusion of feasibility study
Secondary outcome [2] 460483 0
Combined clinical-genetic risk calculator stratification comparability to clinician judgement
Timepoint [2] 460483 0
8 weeks post RGEC visit
Secondary outcome [3] 460484 0
Comparison of RGEC-informed calculation risk stratification and referral information
Timepoint [3] 460484 0
3 months from conclusion of feasibility trial

Eligibility
Key inclusion criteria
- Males and females aged 18 years and over
- Category 2 (appointment within 90 days) or Category 3 (within 365 days) glaucoma referrals
- Able to understand and complete informed consent to enrol in study
- Referred by an optometrist for purpose of glaucoma assessment
- Glaucoma treatment naive i.e no previous or current IOP lowering medication, selective laser trabeculoplasty or surgery in either eye
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
- Category 1 (appointment within 30 days) glaucoma referrals
- Best corrected visual acuity < 6/18
- Comorbid active ocular conditions, excluding cataracts and non-neovascular macular degeneration
- Diagnosed glaucoma and/or current or prior treatment (including use of long-term IOP lowering medication, selective laser trabeculoplasty, or glaucoma surgery)
- Significant cognitive impairment or inability to perform reliable perimetry and obtain informed consent

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA
Recruitment hospital [1] 29399 0
Flinders Medical Centre - Bedford Park
Recruitment postcode(s) [1] 45720 0
5042 - Bedford Park

Funding & Sponsors
Funding source category [1] 321628 0
Government body
Name [1] 321628 0
Department of Health, Disability and Ageing - Medical Research Future Fund (MRFF)
Country [1] 321628 0
Australia
Primary sponsor type
University
Name
Flinders University
Address
Country
Australia
Secondary sponsor category [1] 324452 0
None
Name [1] 324452 0
Address [1] 324452 0
Country [1] 324452 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320153 0
Southern Adelaide Clinical Human Research Ethics Committee
Ethics committee address [1] 320153 0
Ethics committee country [1] 320153 0
Australia
Date submitted for ethics approval [1] 320153 0
Approval date [1] 320153 0
08/12/2025
Ethics approval number [1] 320153 0
2025/HRE00412

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149618 0
Prof Jamie Craig
Address 149618 0
Level 3, Flinders Health and Medical Research Building, Sports Road, Bedford Park, SA 5042
Country 149618 0
Australia
Phone 149618 0
+61 8 8432 4601
Fax 149618 0
Email 149618 0
Contact person for public queries
Name 149619 0
Karli Goodwin
Address 149619 0
Level 3, Flinders Health and Medical Research Building, Sports Road, Bedford Park, SA 5042
Country 149619 0
Australia
Phone 149619 0
+61 8 7221 8487
Fax 149619 0
Email 149619 0
Contact person for scientific queries
Name 149620 0
Jamie Craig
Address 149620 0
Level 3, Flinders Health and Medical Research Building, Sports Road, Bedford Park, SA 5042
Country 149620 0
Australia
Phone 149620 0
+61 8 8432 4601
Fax 149620 0
Email 149620 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.